# OnCo record medulloblastoma-shh (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/medulloblastoma-shh/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "medulloblastoma-shh" ;
  schema:name "SHH-activated medulloblastoma"@en ;
  schema:alternateName "SHH medulloblastoma"@en, "Sonic hedgehog medulloblastoma"@en, "Desmoplastic/nodular medulloblastoma"@en, "SHH-activated TP53-mutant medulloblastoma"@en ;
  schema:description "SHH-activated medulloblastoma is driven by the sonic hedgehog growth pathway, the signal that normally tells the developing cerebellum to grow. In infants it is often cured with chemotherapy alone and no radiotherapy; in adults it responds for a time to hedgehog-blocking pills such as vismodegib; and when it carries a TP53 mutation in an older child, often inherited, it resists everything."@en ;
  schema:url <https://onco.cc/cancers/medulloblastoma-shh/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Medulloblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Medulloblastoma>, <https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/medulloblastoma-wnt/>, <https://onco.cc/cancers/medulloblastoma-group-3-4/>, <https://onco.cc/cancers/basal-cell-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:targets <https://onco.cc/targets/smoothened/>, <https://onco.cc/targets/tp53/> ;
  onco:institutions <https://onco.cc/institutions/st-jude/>, <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:pathways <https://onco.cc/pathways/hedgehog/> ;
  onco:terms <https://onco.cc/terms/li-fraumeni/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/medulloblastoma-molecular-groups/> ;
  onco:pipeline <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:standardOfCare <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/terms/li-fraumeni/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/targets/smoothened/>, <https://onco.cc/pathways/hedgehog/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/secondary-malignancy/> .